A real world retrospective study assessing the efficacy and safety of low-dose Nivolumab in patients with Renal Cell Carcinoma
Latest Information Update: 24 Mar 2021
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 24 Mar 2021 New trial record